Primary refractoriness to platelet transfusion caused by Naka antibody alone

被引:24
|
作者
Fujino, H
Ohta, K
Taniue, A
Nagao, N
Hino, M
Yamane, T
Koh, KR
Takeoka, Y
Hirose, A
Aoyama, Y
Nakamae, H
Terada, Y
Takubo, T
Tatsumi, N
机构
[1] Osaka City Univ, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan
[2] Osaka Red Cross Blood Ctr, Joto Ku, Osaka, Japan
关键词
Nak(a); platelet-specific antibodies; platelet transfusion; transfusion refractoriness;
D O I
10.1046/j.1423-0410.2001.00048.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives Anti-Nak(a), a platelet-specific antibody, occasionally causes platelet-transfusion refractoriness (PTR) together with human leucocyte antigen (HLA) antibodies. Anti-Naka usually appears after frequent platelet transfusions or pregnancy. We report the first case of PTR caused by anti-Nak(a) alone. Materials and Methods A 19-year-old male patient with testicular tumour showed PTR when receiving his first transfusion of platelets. Screening for platelet antigens and platelet antibodies revealed that he had type I CD36 (Nak(a)) deficiency and that anti-Nak(a), but not anti-HLA, was present before he received his first transfusion. Results The transfusion of Nak(a)-negative, but HLA non-selected, platelets was effective in raising the platelet count. Conclusion Clinically significant Nak(a) antibody was present as naturally occurring antibody in a platelet glycoprotein IV (CD36)-negative non-transfused male patient.
引用
收藏
页码:42 / 44
页数:3
相关论文
共 50 条
  • [21] Diagnosis and management of refractoriness to platelet transfusion
    Schiffer, CA
    BLOOD REVIEWS, 2001, 15 (04) : 175 - 180
  • [22] FORMULAS FOR THE DEFINITION OF REFRACTORINESS TO PLATELET TRANSFUSION
    REBULLA, P
    TRANSFUSION MEDICINE, 1993, 3 (01) : 91 - 92
  • [23] Evaluation and management of platelet transfusion refractoriness
    Youk, Hee-Jeong
    Hwang, Sang-Hyun
    Oh, Heung-Bum
    Ko, Dae-Hyun
    BLOOD RESEARCH, 2022, 57 : 6 - 10
  • [24] PLATELET TRANSFUSION REFRACTORINESS DUE TO MULTIPLE HUMAN PLATELET ANTIGEN (HPA) ANTIBODY SPECIFICITIES: A CASE STUDY
    Hopkins, Matthew
    Calvert, Anthony
    Poles, Anthony
    HLA, 2020, 95 (04) : 353 - 353
  • [25] Related donor platelet transfusion improves platelet transfusion refractoriness in hematological patients
    Zhang, Jing-Cheng
    Ni, Li-Hong
    Tu, Yan
    Hu, Hui-Xian
    FRONTIERS IN MEDICINE, 2023, 10
  • [26] Naturally occurring anti-Naka (CD36) mediated platelet refractoriness
    Pomper, GJ
    Joseph, RA
    Li, H
    Young, BJ
    Boyd, TM
    Powell, BL
    TRANSFUSION, 2005, 45 (03) : 100A - 100A
  • [27] The role of HLA epitope mismatches in antibody development and refractoriness to optimize allocation in platelet transfusion
    Matern, Benedict
    Walther, Johanna
    Peereboom, Emma
    Geneugelijk, Kirsten
    Kesmir, Can
    Spierings, Eric
    HLA, 2022, 99 (05) : 432 - 432
  • [28] REFRACTORINESS AND ALLOIMMUNIZATION AFTER PLATELET TRANSFUSION THERAPY
    VOLKOVA, RI
    AGRANENKO, VA
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1992, 37 (02): : 16 - 21
  • [29] Complement as an Immune Barrier in Platelet Transfusion Refractoriness
    Meinke, Stephan
    Karlstrom, Cecilia
    Hoglund, Petter
    TRANSFUSION MEDICINE REVIEWS, 2019, 33 (04) : 231 - 235
  • [30] Avatrombopag for the salvage treatment of platelet transfusion refractoriness
    Qin, Yuehong
    Wang, Yu
    Zhang, Yujiao
    Jiao, Yingying
    Ye, Jieyu
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15